Organization | EuBiologics Co.,Ltd

EuBiologics Co.,Ltd Report issue

For profit Phase 1 Phase 3

Founded: Seoul Korea, Republic of (2010)

Organization Overview

First Clinical Trial

2012

NCT01707537

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

EuBiologics Co.,Ltd

Active Ingredients

Drugs in Phase 3 Trials (8)

abobotulinumtoxinA (Dysport) (2 trials)

chadox1 (2 trials)

cholera vaccine (Vaxchora) (3 trials)

eucorvac-19 (3 trials)

killed oral cholera vaccine (4 trials)

onabotulinumtoxinA (Botox) (1 trial)

typhoid vaccine (1 trial)

typhoid vi polysaccharide vaccine (Typhim Vi) (2 trials)

Drugs in Phase 1 Trials (7)

15-valent pneumococcal conjugate vaccine (VAXNEUVANCE) (1 trial)

eunmcv-5 (1 trial)

meningococcal conjugate vaccine (Menveo) (1 trial)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) (1 trial)

monoaluminum phosphate (1 trial)

osp:rtthc (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cholera (Phase 3)

Typhoid Fever (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 15
# of Trial APIs: 15